Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

23.86 +0.98 (+4.28%)
Streaming Delayed Price Updated: 11:20 AM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 115,349
Open 23.17
Bid (Size) 23.83 (200)
Ask (Size) 23.88 (100)
Prev. Close 22.88
Today's Range 23.10 - 23.97
52wk Range 9.030 - 28.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading... 
Via Benzinga
Topics Stocks

Performance

YTD
-10.4%
-10.4%
1 Month
+5.6%
+5.6%
3 Month
-8.1%
-8.1%
6 Month
+49.8%
+49.8%
1 Year
+89.7%
+89.7%

More News

Read More
News headline image
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Zymeworks Inc (NASDAQ:ZYME) Posts Wider Q4 Loss Despite Strategic Progress and Royalty Deal ↗
Via Chartmill
ZYMEWORKS INC (NASDAQ:ZYME) Fits the Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
News headline image
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Outlines Strategic Priorities and Outlook for 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
Via Chartmill
News headline image
Zymeworks Announces Participation in Upcoming Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes ↗
Via Stocktwits
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
Via FinancialNewsMedia
News headline image
Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗
Via Benzinga

Frequently Asked Questions

Is Zymeworks Inc. - Common Stock publicly traded?
Yes, Zymeworks Inc. - Common Stock is publicly traded.
What exchange does Zymeworks Inc. - Common Stock trade on?
Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zymeworks Inc. - Common Stock?
The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
What is the current price of Zymeworks Inc. - Common Stock?
The current price of Zymeworks Inc. - Common Stock is 23.86
When was Zymeworks Inc. - Common Stock last traded?
The last trade of Zymeworks Inc. - Common Stock was at 03/16/26 11:20 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.